New combo targets tough lung cancer with promising drug

NCT ID NCT06194448

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests whether giving the targeted drug osimertinib before and after standard chemoradiation helps control stage III lung cancer that cannot be removed by surgery. About 76 adults with a specific EGFR gene mutation will receive the drug as induction therapy, then continue it as maintenance after chemoradiation. The goal is to see if this approach delays cancer growth and is safe, but patients will need ongoing medication to manage the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

Research Site

La Jolla, California, 92093, United States
Research Site

Palo Alto, California, 94304, United States
Research Site

Beijing, 100021, China
Research Site

Changsha, 410013, China
Research Site

Guangzhou, 510060, China
Research Site

Hangzhou, 310022, China
Research Site

Harbin, 150081, China
Research Site

Hefei, 230001, China
Research Site

Jinan, 250117, China
Research Site

Nanning, 530021, China
Research Site

Shanghai, 200032, China
Research Site

Tianjin, 300060, China
Research Site

Wuhan, 430022, China
Research Site

Wuhan, 430071, China
Research Site

Zhengzhou, 450052, China
Research Site

Haifa, 31096, Israel
Research Site

Jerusalem, 91031, Israel
Research Site

Tel Aviv, 62748, Israel
Research Site

Cheongju-si, 28644, South Korea
Research Site

Seongnam-si, 13620, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Suwon, 16247, South Korea
Research Site

Barcelona, 08003, Spain
Research Site

Donostia / San Sebastian, 20014, Spain
Research Site

Granada, 18016, Spain
Research Site

Madrid, 28007, Spain
Research Site

Tainan, 704, Taiwan
Research Site

Taipei, 11217, Taiwan
Research Site

Bangkok, 10210, Thailand
Research Site

Bangkok, 10330, Thailand
Research Site

Chiang Rai, 57000, Thailand
Research Site

Hat Yai, 90110, Thailand
Research Site

Khon Kaen, 40002, Thailand
Research Site

Ankara, 06010, Turkey (Türkiye)
Research Site

Yenimahalle, 06560, Turkey (Türkiye)
Research Site

Hanoi, 100000, Vietnam
Research Site

Ho Chi Minh City, 700000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.